Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00115154 · ClinicalTrials.gov registry record · Phase 4
Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands
A Phase 4 study of Keratosis, sponsored by Graceway Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 270
- Enrollment target
- 18
- Study locations
NCT00115154 is a Phase 4 study of Keratosis that has completed, run by Graceway Pharmaceuticals. The registered enrollment target is 270 participants. The trial reports 18 study locations across 15 states.
The verdict
NCT00115154, a Phase 4 study of Keratosis, has completed, sponsored by Graceway Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 270 participants
- Enrollment target
- 18
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of imiquimod 5% cream compared to vehicle cream in the treatment of Actinic Keratosis (AK) on the arm and/or hand when the cream is applied once daily 2 days per week for 16 weeks.
Conditions Studied
Interventions
- DRUG Aldara (imiquimod) cream, 5%
Study Locations (18)
Georgia
- - Atlanta
- - Newnan
New York
- - New York
- - Rochester
Texas
- - Dallas
- - Houston
Arizona
- - Tucson
California
- - Vista
Illinois
- - Buffalo Grove
Indiana
- - Evansville
New Jersey
- - Riverside Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2005-05 |
| Est. Completion | 2006-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00115154
The ClinicalTrials.gov registry entry for NCT00115154 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 270 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Graceway Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Keratosis appearing as the primary indexed condition, and to 1 intervention - of which Aldara (imiquimod) cream, 5% is the first listed.
NCT00115154 reports 18 study locations spanning 15 distinct geographic areas - top geographies include Georgia, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT00115154 about?
NCT00115154 is a clinical study titled "Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands". The purpose of this study is to evaluate the safety and efficacy of imiquimod 5% cream compared to vehicle cream in the treatment of Actinic Keratosis (AK) on the arm and/or hand when the cream is applied once daily 2 days per week for 16 weeks.
What is the current status of trial NCT00115154?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 270 participants. The study started on 2005-05. Estimated completion is 2006-09.
What conditions does trial NCT00115154 study?
This clinical trial studies the following conditions: Keratosis.
What interventions are being tested in trial NCT00115154?
The interventions under investigation include: Aldara (imiquimod) cream, 5% (DRUG).
Who is sponsoring clinical trial NCT00115154?
This trial is sponsored by Graceway Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00115154 being conducted?
This trial has 18 study locations across Arizona, California, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Keratosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.